The study found that administering 160 mg of osimertinib to patients with EGFRm NSCLC and LM who had progressed after prior EGFR-TKI therapy resulted in a remission duration of 8.3 months, an ORR of 41%, a median PFS of 8.6 months, and a median OS of 11.0 months, with a manageable safety profile (40). This evidence concerns the gene EGFR and non-small cell lung carcinoma.